TERAZOL 7
LOE ApproachingNDAVAGINALCREAM
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TERAZOL 7 is a vaginal cream antifungal medication approved in 1987 for the treatment of vaginal yeast infections. The product is a small-molecule formulation delivered topically to the vaginal mucosa. Mechanism of action and specific pharmacologic class data are not available in current records.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30); teams should expect transition planning and potential portfolio rationalization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TERAZOL 7 currently shows zero linked job openings, reflecting its mature, late-lifecycle status. Career opportunities on this asset are limited to defensive and operational roles focused on market maintenance and compliance rather than growth or innovation initiatives.
Brand ManagerProduct Manager
Worked on TERAZOL 7 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.